Butyric acid

Verb Biotics Announces Data from Preclinical Studies to Support Foundational Gut Microbiome Health from Newly Launched Keystone Postbiotic™

Retrieved on: 
Tuesday, March 19, 2024
Health, Antioxidant, Keystone, Powder, Capsule, Probiotic, Butyric acid, Functional food, Overalls, Cytokine, MOA, Drink, Water, Prebiotic (nutrition), Immune system, Caco-2, Vaccine

BOSTON, March 19, 2024 /PRNewswire/ -- Verb Biotics, a microbiome health ingredient company, today announced preliminary preclinical data from their newly launched Keystone Postbiotic™, a foundational gut microbiome solution to help support and strengthen gut microbiome health.

Key Points: 
  • BOSTON, March 19, 2024 /PRNewswire/ -- Verb Biotics, a microbiome health ingredient company, today announced preliminary preclinical data from their newly launched Keystone Postbiotic™, a foundational gut microbiome solution to help support and strengthen gut microbiome health.
  • Verb Biotics has conducted thorough in-vitro and preliminary human studies to understand how Keystone Postbiotics' deliberately chosen active components contribute to maintaining a robust gut microbiome and a well-regulated immune response.
  • The preclinical data contributed to the decision by Verb Biotics to commence human clinical studies in January 2024 to evaluate the potential support of foundational gut microbiome health by Keystone Postbiotic™.
  • Keystone Postbiotic™ combines strains, grains, and botanicals to deliver functional redundancy to support foundational gut microbiome health.

Pendulum Therapeutics Introduces GLP-1 Probiotic

Retrieved on: 
Wednesday, March 13, 2024
Health, Brain, Disease, Appetite, Insulin, Clostridium butyricum, Butyric acid, Therapy, Pancreas, Ecosystem, Safety, Stomach, Pendulum, Dietary supplement

SAN FRANCISCO, March 13, 2024 /PRNewswire/ -- Pendulum Therapeutics, a female-led biotech company pioneering the next frontier of metabolic health through its microbiome-targeted products, announces the launch of their GLP-1 Probiotic. This revolutionary product empowers people to take control of their metabolic health by naturally increasing GLP-1, the "un-hunger" hormone that the body naturally produces when you eat. The Pendulum probiotic is formulated with beneficial bacterial strains known to stimulate GLP-1 production (based on preclinical studies), and reduce appetite and cravings. Participants in GLP-1 Probiotic consumer research reported significant reduction in food cravings after 6 weeks. 91% reported reduced overall food cravings and 88% reported reduced sugar cravings.

Key Points: 
  • GLP-1 Probiotic is a powerful, effective, and science-backed tool to help naturally boost GLP-1 production and naturally help maintain a healthy weight*
    SAN FRANCISCO, March 13, 2024 /PRNewswire/ -- Pendulum Therapeutics , a female-led biotech company pioneering the next frontier of metabolic health through its microbiome-targeted products, announces the launch of their GLP-1 Probiotic.
  • The Pendulum probiotic is formulated with beneficial bacterial strains known to stimulate GLP-1 production (based on preclinical studies), and reduce appetite and cravings.
  • Participants in GLP-1 Probiotic consumer research reported significant reduction in food cravings after 6 weeks.
  • "We are proud to extend the Pendulum probiotic portfolio with the launch of GLP-1 Probiotic.

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Medical Subject Headings, Marketing, European Commission, Agency, Neuropathic pain, INN, Risk, ATC, Capsule, International, European, Spinal cord, Language, Butyric acid, Brain, Anxiety disorder, Anxiety, GAD, Nervous, Peripheral neuropathy, Zentiva, Select, Committee, Patient, Risk management, Anatomy, Medicine, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Date of authorisation: 10/04/2014, Revision: 30, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Pfizer, European Commission, Agency, Neuropathic pain, INN, ATC, Pain, Capsule, International, European, Spinal cord, Diabetes, Language, Butyric acid, Brain, Somnolence, Shingles, Anxiety disorder, Nerve, Dizziness, Anxiety, Water, GAD, Nervous, CHMP, Peripheral neuropathy, Select, Risk management, Anatomy, Medicine, Chronic pain, Seizure, IIA, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Date of authorisation: 10/04/2014, Revision: 30, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Date of authorisation: 10/04/2014, Revision: 30, Status: Authorised

Butyric Acid Derivatives Global Strategic Business Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 17, 2023
Chemicals, Plastics, Manufacturing, Pig, Compound annual growth rate, Growth, Butyric acid, Livestock, Poultry, Coal, Pet industry

The "Butyric Acid Derivatives - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Butyric Acid Derivatives - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Butyric Acid Derivatives estimated at US$496.9 Million in the year 2022, is projected to reach a revised size of US$886.1 Million by 2030, growing at a CAGR of 7.5% over the analysis period 2022-2030.
  • The report presents insights into recent past, current, and future sales trends, accompanied by percentage Compound Annual Growth Rates (CAGR) where applicable.
  • The Butyric Acid Derivatives market in the U.S. is estimated at US$78.7 Million in the year 2022.

Animal Disease Management Spurs Adoption of Butyric Acid Derivatives, Projected CAGR of 7.5% by 2030

Retrieved on: 
Wednesday, August 23, 2023
Butyric acid, Growth, Coal, Pet industry

DUBLIN, Aug. 23, 2023 /PRNewswire/ -- The "Butyric Acid Derivatives: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 23, 2023 /PRNewswire/ -- The "Butyric Acid Derivatives: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Butyric Acid Derivatives estimated at US$496.9 Million in the year 2022, is projected to reach a revised size of US$886.1 Million by 2030, growing at a CAGR of 7.5% over the analysis period 2022-2030.
  • Sodium Butyrate, one of the segments analyzed in the report, is projected to record a 7.9% CAGR and reach US$438.9 Million by the end of the analysis period.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$246.2 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2022 to 2030.

Microba Launches Next Generation Healthcare Testing

Retrieved on: 
Tuesday, February 28, 2023
Medical Supplies, Biotechnology, Health, General Health, Pharmaceutical, Other Science, Medical Devices, Research, Infectious Diseases, Science, Clinical Trials, Parasitism, Bacteria, Cyclospora cayetanensis, Yersinia enterocolitica, Annual report, Lactoferrin, Fungus, Butyric acid, Methane, ASX, File association, Lipopolysaccharide, Giardia duodenalis, Immunoglobulin A, Health professional, TMA, Pancreatic elastase, Stool test, Entamoeba histolytica, Microorganism, Completeness, IPA, BCAA, Multimedia, MAP, Diagnosis, Pharmaceutical industry, Antibiotics, Blastocystis

Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™.

Key Points: 
  • Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™.
  • The MetaXplore™ test range has been developed together with healthcare professionals and brought to market under a new brand called Co-Biome™.
  • The MetaXplore™ test range through Co-Biome™ represents an important step forward in that strategy by breaking new ground in the application of microbiome testing in healthcare.
  • Microba’s Chief Scientific Officer, Assoc Prof. Lutz Krause said, “These new tests integrate traditional gastrointestinal pathology tools with Microba’s next generation microbiome testing technology and the latest global research to significantly advance the utility of microbiome testing in a healthcare setting.

ClostraBio Announces Breakthrough Publication Describing Targeted Delivery of Metabolite to Gastrointestinal Tract via Oral Nanoparticles; Appoints CEO

Retrieved on: 
Tuesday, January 24, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, SCFA, Pyxis, Colon, Mouse, Ulcerative colitis, Taste, Food, Inflammatory bowel disease, Food allergy, Nature Biomedical Engineering, Nanoparticle, Drug development, Micelle, Patient, News, Colitis, Peanut allergy, University, Butyric acid, IBD, Gastrointestinal tract, University of Chicago, Pharmaceutical industry, Medical device

ClostraBio, a biotech company focused on developing novel therapeutic solutions for diseases of the gut, is excited to announce a major breakthrough in targeted metabolite delivery to transform intestinal health.

Key Points: 
  • ClostraBio, a biotech company focused on developing novel therapeutic solutions for diseases of the gut, is excited to announce a major breakthrough in targeted metabolite delivery to transform intestinal health.
  • This first-in-class, oral, targeted metabolite delivery platform enables butyrate to achieve its maximum therapeutic potential with an initial focus on helping patients who struggle with gastrointestinal issues like mild to moderate ulcerative colitis and food allergies.
  • ClostraBio co-founder, Dr. Jeffrey Hubbell said, “In today’s options for gastrointestinal issues, targeted drug delivery has become key in pharmaceutical product development.
  • ClostraBio is a late-preclinical stage biopharma company focused on targeted metabolite delivery to transform intestinal health in patients with inflammatory bowel disease (IBD) and food allergy.

Dr. Steven Gundry's Gundry MD Bio Complete 3 Celebrates Over 2 Million Units Sold in 2022

Retrieved on: 
Friday, February 10, 2023
Steven Gundry, Probiotic, Dietary fiber, Health, Immune system, Bacteria, Butyric acid, Postbiotic, Prebiotic (nutrition), LOS, Nutritional science, Gastrointestinal tract, Digestion, Gum arabic, Dietary supplement, Food delivery, Gundry

LOS ANGELES, Feb. 10, 2023 /PRNewswire/ -- Gundry MD™ Bio Complete 3, one of the brand's best-selling supplements, celebrates sales of over two million units in 2022. Formulated by world-renowned heart surgeon and medical researcher Dr. Steven Gundry, this unique 3-pronged blend of probiotics, prebiotics, and postbiotics was crafted to support optimal gut health. Gundry MD Bio Complete 3 is the complete gut health package as it is the first product on the U.S. market to introduce CoreBiome™. CoreBiome is a one-of-a-kind postbiotic that helps users enjoy an "ironclad" gut lining by supporting greater energy levels and minimizing cravings for unhealthy foods for a slimmer waistline.†*

Key Points: 
  • Gundry MD Bio Complete 3 is the complete gut health package as it is the first product on the U.S. market to introduce CoreBiome™.
  • Gundry MD Bio Complete 3 is a revolutionary all-in-one dietary supplement containing prebiotics, probiotics, and postbiotics.
  • Prebiotics in Gundry MD Bio Complete 3 help fuel the good bacteria in the gut, allowing them to thrive.
  • The suggested use of Gundry MD Bio Complete 3 is to simply take two small capsules twice per day, preferably before a meal.

Gut Health Pioneer Supergut Publishes Groundbreaking Clinical Study in Journal "Diabetes, Obesity and Metabolism"

Retrieved on: 
Wednesday, February 1, 2023
Synthetic control method, Sleep, Human, Bill, Obesity, Metabolism, Clinical trial, Digestion, Diabetes, Research, Health, Starch, Butyric acid, Therapy, Stanford University, Plasma protein binding, Science, Glycated hemoglobin, Bacteria, Functional food, Public, Injection, Quality of life, Bill & Melinda Gates Foundation, Blood pressure, Overalls, LOS, Pharmaceutical industry, Animal feed, Dietary supplement, Pharmacology, MD

LOS ANGELES, Feb. 1, 2023 /PRNewswire/ -- Breakthrough gut health nutrition brand Supergut had its peer-reviewed, clinical trial published this week in the highly-respected journal Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics – an interdisciplinary journal for high-quality research and reviews in the areas of diabetes, obesity and metabolism.

Key Points: 
  • Supergut's clinical trial builds on the growing body of evidence validating the importance of gut health on various dimensions of health.
  • To the brand's knowledge, the Supergut study is the first commercially available, non-pharmaceutical intervention to be published in this high-credibility medical journal.
  • Supergut's study also marks the first clinical trial on resistant starch fiber from a food-tech company.
  • Supergut is the only gut health nutrition company that has performed and published such rigorous clinical results, setting a new standard in the supplement and gut health industry.